Аргументы в пользу применения современных блокаторов H1-гистаминовых рецепторов для лечения больных с аллергическим ринитом, протекающим на фоне острой респираторной вирусной инфекции

Abstract

Allergic rhinitis is characterized by a significant prevalence among the adult population. Patients with allergic diseases have a higher sensitivity to pathogens of acute respiratory infection of the upper respiratory tract (ARVI). Inflammation of the mucous membrane of the nasal cavity and paranasal sinuses in such patients is characterized by more pronounced symptoms and greater resistance to therapy. An observational study was conducted at the Department of Otorhinolaryngology of the Moscow State Medical University named after A. I. Evdokimov, during which the effect of modern antihistamines on the severity of nasal and non-nasal symptoms of inflammation was evaluated in patients who were diagnosed with the development of acute respiratory viral infections against the background of seasonal exacerbation of allergic rhinitis. The data of 50 patients divided into two groups were analyzed. In the first group (n = 25), benzhydrylpiperazinylbutylmethylxanthine succinate (Theoritin) was included in the therapy regimen, in the second – cetirizine preparations (n = 5). During the follow-up, each patient underwent a clinical assessment of the severity of nasal and non-nasal symptoms three times (1st, 7th and 14th days of follow-up), and the severity of nasal obstruction was assessed using anterior active rhinomanometry. According to the data obtained, there was a pronounced positive dynamics in both groups, while the clinical efficacy was confirmed by instrumental evaluation data. However, by the 7th day of treatment, the positive dynamics was more pronounced in the group of patients receiving theoritin as part of therapy. The use of modern antihistamines in patients comorbid for allergic rhinitis and acute respiratory diseases has a significant therapeutic effect. Theoritin provides more pronounced therapeutic effects in the early stages, which makes its further study and use of the drug for the treatment of acute respiratory viral infections against the background of allergic rhinitis promising.